A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes.
Saved in:
| Title: | A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes. |
|---|---|
| Authors: | Shin, Sun-Hye1 (AUTHOR) s1sunhye@naver.com, Kim, Hee-Yeon1 (AUTHOR) heeyeon1432@gmail.com, Yoon, Hee-Soo1 (AUTHOR) gltn129@naver.com, Park, Woo-Jae2 (AUTHOR) ooze@gachon.ac.kr, Adams, David R.3 (AUTHOR) D.R.Adams@hw.ac.uk, Pyne, Nigel J.4 (AUTHOR) n.j.pyne@strath.ac.uk, Pyne, Susan4 (AUTHOR) susan.pyne@strath.ac.uk, Park, Joo-Won1 (AUTHOR) joowon.park@ewha.ac.kr |
| Source: | International Journal of Molecular Sciences. Nov2020, Vol. 21 Issue 21, p8371. 1p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
